StreetAlpha.app
Home › Stocks › VIR

Vir Biotechnology, Inc. (VIR)

Healthcare
$9.25
▼ −3.44%
LAST CLOSE · NOV 17

Vir Biotechnology develops product candidates for serious infectious diseases and cancer. It last closed at $9.25 on Nov 17, down 3.44% on the day. The average 12-month price target from 4 analysts is $24.75 (+167.6% from the last close), with a high of $28.00 and a low of $22.00. Analyst consensus is Strong Buy, based on the latest ratings from 4 firms (4 buy, 0 hold, 0 sell). In the past 30 days there were 1 dark pool print totaling $435K, the largest $435K.

AI Auto Pilots
Is VIR in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$302.8M
+1696.0% vs a year ago
Net income
−$184.8M
−61.0% margin
EPS (diluted)
−$1.18
Free cash flow
−$141.8M
−46.8% margin
Valuation
Market cap
$1.6B
171.3M shares
P/E
–
No P/E while losing money
Price to sales
5.2
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$218.9M
At Sep 30
Shareholder equity
$896.0M
Shares outstanding
171.3M
At Oct 28
CEOGeorge Scangos
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $1.1B$1.1BFY2021FY2022: $1.6B$1.6BFY2022FY2023: $86.2M$86.2MFY2023FY2024: $74.2M$74.2MFY2024FY2025: $68.6M$68.6MFY2025

From VIR's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 4). Last 12 months adds up the four latest quarters.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Strong Buy
Based on 4 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
4firms
4 Buy0 Hold0 Sell
Each firm's latest rating on VIR in the past 90 days
Average 12-month target
$24.75
▲ 167.6% upside

Based on 4 analysts who set a price target on VIR in the past 90 days. The average target is $24.75, with a high of $28.00 and a low of $22.00, compared with the last close of $9.25.

Low $22.00Avg $24.75High $28.00
Blue marker: last close $9.25
Highest target$28.00
Average target$24.75
Lowest target$22.00
Latest rating changes
Morgan StanleyTarget raised
Nov 10Buy$27 → $28
Evercore ISI GroupMaintained
Nov 10Buy$25
NeedhamTarget raised
Nov 10Buy$20 → $24
NeedhamMaintained
Nov 5Buy$20
HC Wainwright & Co.Maintained
Oct 7Buy$22
DateFirmActionRatingPrice target
Nov 10Morgan StanleyTarget raisedBuy$27 → $28
Nov 10Evercore ISI GroupMaintainedBuy$25
Nov 10NeedhamTarget raisedBuy$20 → $24
Nov 5NeedhamMaintainedBuy$20
Oct 7HC Wainwright & Co.MaintainedBuy$22
Loading…

Technical Analysis

VIR · as of the Nov 17 close · updated after every close
Pullback inside a longer uptrend, nearing oversold

The stock is 23% below its 20 day and 20% below its 50 day average. It is 6% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 37), near oversold. The nearest support is the swing low (Jul 20) at $9.11, and the nearest resistance the Pivot at $9.34.

Short trendBearish
Long trendBullish
MomentumWeak
StretchNear oversold
VolatilityHigh, 9.4%/day
Key levels
$14.3752 week high+55.4%
$11.3620 day average+22.8%
$11.0750 day average+19.7%
$10.42100 day average+12.6%
$9.78200 day average+5.7%
$9.70Swing high (Aug 6)+4.9%
$9.66Pivot R1+4.4%
$9.34Pivot+1.0%
$9.25Last close
$9.11Swing low (Jul 20)−1.5%
$8.94Pivot S1−3.4%
$5.3252 week low−42.5%
Indicators
RSI (14)37.08Weak, oversold below 30Neutral
MACD-0.10Below its signal lineBearish
Stochastic3.2Near the bottom of its rangeOversold
ADX (14)23.7Weak trend
Williams %R-95.9Oversold below −80, overbought above −20Oversold
CCI (20)-160.6Oversold below −100, overbought above 100Oversold
Rate of change−17.6%Change over 10 sessionsBearish
ATR (14)$0.87Typical daily range, 9.4% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for VIR

What happened before

See how VIR did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow VIR usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How VIR has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2019.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in VIR in the last 90 days.

Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
1
Notional
$435K
Largest print
$435K
Loading…

VIR Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲137 buying vs 108 selling
  • ▼Held by funds -3.8 pts
  • ▲Funds holding +29
  • ▼Superinvestors: 1 added, 3 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding266237+12.2%
In funds' top 1056−16.7%
Held by funds81.8%85.6%−3.8 pts
New / increased53 / 8431 / 94+9.6%
Reduced / sold out85 / 2375 / 43−8.5%
Put/call ratio6.180.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See VIR institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether VIR is in one of them and how their past VIR trades turned out.

VIR in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered VIR in an article yet. Here's the latest on the wider market.

About Vir Biotechnology

Vir Biotechnology is a biotechnology company based in San Francisco, California. It is developing product candidates, none yet approved, for serious infectious diseases and cancer, built on several technology platforms. The company also works with other drugmakers through collaboration and licensing agreements, both acquiring rights to some candidates and granting rights to others for further development.

Headquarters
San Francisco, CA
Founded
2016